Table 3 Outcome data concerning PRS stratified by the Heidelberg score; subgroups with and without bevacizumab are shown
Heidelberg score/group | Entire cohort, PRS [months] | Bevacizumab, PRS [months] | No bevacizumab, PRS [months] |
|---|---|---|---|
Excellent | 7 | 7 | -- |
Good | 7 | 8 | 2 |
Moderate | 9 | 9 | -- |
Poor | 7 | 8 | 6 |
P-value | ns (p = 0.664) | ns (p = 508) | ns (p = 0.316) |